Can you get Wegovy in pill form? Yes — here is what the UK approved

What exactly is in the Wegovy pill, and how does it reach your bloodstream?

The challenge with swallowing any GLP-1 medicine is stomach acid — left unprotected, semaglutide breaks down before it can be absorbed. Novo Nordisk solved this by co-formulating semaglutide with a compound called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino]caprylate), which briefly raises the local pH in the stomach wall and helps the drug pass through into circulation. If you want a broader picture of what the Wegovy tablet form involves, including how it differs from the injection in practical terms, that page is a useful starting point. The result is a small tablet that, taken correctly, delivers a meaningful dose of semaglutide without an injection.

One practical detail matters: the tablet has to be taken first thing in the morning, on a completely empty stomach, with a small sip of plain water, up to about 120 millilitres. Then you wait at least 30 minutes before eating, drinking anything else (including coffee or tea), or taking any other oral medicines. Swallow it whole. If you want to check this for yourself before your first dose, the patient information leaflet is published on the electronic Medicines Compendium, a one-minute read that confirms the exact routine. The tablet does not need refrigeration, which is a meaningful practical difference from the weekly injection.

The dosing schedule starts at 1.5mg and steps up through 4mg and 9mg to a 25mg maintenance dose, with at least a month at each level. A prescriber manages that titration; it is not something to self-adjust.

What did the clinical trial actually show for the tablet form of Wegovy?

The OASIS 4 trial was a phase-3 study involving 307 adults with obesity or overweight alongside at least one weight-related condition, none of whom had type 2 diabetes. Participants followed the oral semaglutide schedule for 64 weeks alongside lifestyle guidance, and results were compared with placebo. The MHRA's approval announcement and Novo Nordisk's published data both report an average weight loss of approximately 13.6% in the semaglutide group versus around 2.4% on placebo, regardless of how strictly participants followed the regimen.

Among those who adhered fully throughout the 64 weeks, average weight loss reached approximately 17%. That figure is worth keeping in perspective: it reflects the best-case group in a controlled trial setting, not a typical real-world average. Both numbers are meaningful, and the gap between them is a useful reminder of why consistency with the morning routine matters. You can read more about the trial evidence behind the Wegovy tablet if you want the deeper breakdown.

The most commonly reported side effects were gastrointestinal (nausea, vomiting, diarrhoea and constipation) experienced by roughly 74% of the semaglutide group compared with 42% on placebo. These were generally mild to moderate and tended to ease as the body adjusted, particularly during dose escalation. The NHS semaglutide medicines page covers the full side-effect profile in plain language.

Who does the UK licence for the Wegovy tablet actually cover?

The MHRA licensed the Wegovy tablet for adults with a BMI of 30 or above, or a BMI between 27 and 29.9 where at least one weight-related condition is present, examples include high blood pressure, raised cholesterol, obstructive sleep apnoea, or prediabetes. These thresholds can sit around 2.5 kg/m² lower for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, in line with UK guidance on ethnic-background risk.

The licence is for use alongside a reduced-calorie diet and increased physical activity, not as a standalone fix. It is also worth being clear about a common mix-up: Rybelsus is a separate oral semaglutide product, licensed specifically for type 2 diabetes at different strengths (3mg, 7mg and 14mg). Those are not steps on the Wegovy tablet schedule, and the two products are not interchangeable. The Wegovy tablet's steps (1.5mg, 4mg, 9mg, 25mg) are distinct.

The tablet is not currently available on the NHS; a NICE appraisal would need to happen first. At launch it is available through private prescription only. If you are already on the 2.4mg weekly injection and wondering about switching, that is a clinical conversation: the MHRA guidance notes that people established on 2.4mg semaglutide injection may move directly to the 25mg tablet, subject to their prescriber's assessment. Details of how the Wegovy tablet is accessed in the UK are worth reading alongside this page.

So is the tablet a straightforward alternative to the injection?

For many people, yes, particularly those who find weekly self-injection daunting, or who travel frequently and would rather skip the cold-chain logistics. No needles, no fridge, no sharps disposal. That is a genuine quality-of-life difference.

The trade-off is that the morning routine is non-negotiable. Forgetting to wait the 30 minutes, or taking it with a coffee, meaningfully reduces how much semaglutide is absorbed. The injection, once in the skin, does not depend on an empty stomach. Neither option is objectively better, it depends on your lifestyle, your preferences and your clinical picture. There is a fuller overview of the Wegovy pill form if you want to compare the two side by side, and our guide to Wegovy tablet costs in the UK covers what private treatment typically involves financially.

If you would like to discuss whether the tablet or the injection suits you better, our prescribers can work through that with you. Speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered clinician, with no obligation to proceed.